PMN Q3 EPS Forecast Raised by Brookline Capital Markets

Promis Neurosciences (NASDAQ:PMN) – Research analysts at Brookline Capital Markets increased their Q3 2026 earnings estimates for shares of Promis Neurosciences in a report released on Friday, August 14th. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will post earnings per share of ($1.29) for the quarter, up from their prior estimate of ($2.41). Brookline Capital Markets currently has a “Strong-Buy” rating on the stock. The consensus estimate for Promis Neurosciences’ current full-year earnings is ($4.97) per share. Brookline Capital Markets also issued estimates for Promis Neurosciences’ Q4 2026 earnings at ($1.34) EPS, FY2026 earnings at ($5.21) EPS, Q1 2027 earnings at ($1.63) EPS, Q2 2027 earnings at ($1.65) EPS, Q3 2027 earnings at ($1.69) EPS, Q4 2027 earnings at ($1.83) EPS and FY2027 earnings at ($6.83) EPS.

A number of other research firms have also recently commented on PMN. Weiss Ratings cut shares of Promis Neurosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Guggenheim reaffirmed a “buy” rating and set a $69.00 price target (up from $35.00) on shares of Promis Neurosciences in a research note on Tuesday, July 28th. Chardan Capital set a $20.00 price objective on shares of Promis Neurosciences and gave the stock a “buy” rating in a report on Monday, July 27th. Roth Capital started coverage on Promis Neurosciences in a research note on Tuesday, July 7th. They set a “buy” rating and a $19.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Promis Neurosciences in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Promis Neurosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.50.

Promis Neurosciences Stock Up 2.2%

NASDAQ PMN opened at $14.98 on Wednesday. Promis Neurosciences has a fifty-two week low of $6.27 and a fifty-two week high of $27.40. The business has a 50 day moving average price of $12.96 and a two-hundred day moving average price of $13.69. The stock has a market cap of $134.34 million, a PE ratio of -1.75 and a beta of -0.23.

Promis Neurosciences (NASDAQ:PMN) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.10.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Seven Fleet Capital Management LP acquired a new position in shares of Promis Neurosciences in the 1st quarter valued at about $135,000. Janus Henderson Group PLC acquired a new stake in shares of Promis Neurosciences during the 1st quarter worth approximately $16,418,000. Ally Bridge Group NY LLC lifted its holdings in shares of Promis Neurosciences by 66.1% in the 1st quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock worth $5,261,000 after purchasing an additional 164,880 shares during the last quarter. Yu Fan acquired a new position in Promis Neurosciences during the 1st quarter valued at approximately $4,188,000. Finally, ADAR1 Capital Management LLC bought a new position in Promis Neurosciences during the 1st quarter worth $1,211,000. 50.13% of the stock is currently owned by institutional investors.

About Promis Neurosciences

Promis Neurosciences, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small?molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.